Table 4 β-Catenin membranous and nuclear expression in 222 invasive breast carcinomas (17C2 clone)

From: β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation

Parameter	N	Membranous negative	Membranous reduced	Membranous positive	P-value	Nuclear negative	Nuclear positive	P-value
Size—TNM	221				0.300			0.917
T1		22	9	83		107	7
T2		20	14	58		85	7
T3		5	1	9		14	1
Grade	217				0.426			0.203
1		2	2	19		23	0
2		17	6	40		60	3
3		27	15	89		119	12
LVI	220				0.012			0.570
Negative		23	9	39		65	6
Positive		24	15	110		140	9
LN mets	215				0.514			0.009
Negative		14	10	48		62	10
Positive		33	13	97		138	5
ER	222				0.074			<0.001
Negative		14	4	22		30	10
Positive		34	20	128		177	5
PR	222				0.017			0.001
Negative		21	5	35		51	10
Positive		27	19	115		156	5
HER2	222				0.485			0.138
Negative		43	19	129		176	15
Positive		5	5	21		31	0
HER2 CISH	211				0.236			0.228
Not amp		43	18	120		167	14
Amp		5	6	19		30	0
EGFR	222				0.719			0.034
Negative		43	21	138		191	11
Positive		5	3	12		16	4
CK14	220				0.244			<0.001
Negative		41	21	140		193	9
Positive		6	3	9		12	6
CK5/6	214				0.894			0.002
Negative		40	21	131		183	9
Positive		5	3	14		16	6
CK17	219				0.159			0.076
Negative		40	19	135		183	11
Positive		7	5	13		21	4
Basal CKs	220				0.421			0.002
Negative		39	19	131		181	8
Positive		8	5	18		24	7
Basal CKs or EGFR	220				0.224			<0.001
Negative		36	19	129		178	6
Positive		11	5	20		27	9
P53	208				0.218			0.027
Negative		30	15	104		143	6
Positive		18	7	34		51	8
MIB-1	207				0.788			0.001
<10%		16	10	59		81	4
10–30%		22	10	60		88	4
>30%		9	3	18		23	7
Molecular subtype ^a	216				0.096			<0.001
Basal		10	3	14		19	8
HER2		5	6	21		32	0
Luminal		30	14	113		152	5
Triple-negative	218				0.006			<0.001
No		35	21	133		183	6
Yes		13	3	13		20	9
E-cadherin	201				<0.001			0.710
Negative		33	7	18		53	5
Reduced		3	2	9		13	1
Normal		9	13	107		122	7
TOP2A	196				0.365			0.266
Low		16	10	65		87	4
High		27	12	66		95	10
TOP2A CISH	211				0.201			0.610
Not amp		44	19	131		180	14
Amp		4	4	9		17	0
Cyclin D1	208				0.044			0.057
Low		11	3	10		20	4
Intermediate		9	3	30		38	4
High		27	17	98		136	6
CCND1 CISH	221				0.185			1.000
Not amp		42	18	132		179	13
Amp		6	6	17		27	2
MYC CISH	184				0.725			0.021
Not amp		36	18	113		158	9
Amp		3	1	13		13	4
Caveolin 1	222				0.040			<0.001
Negative		39	23	139		193	8
Positive		9	1	11		14	7
Caveolin 2	196				0.484			0.001
Negative		41	20	123		175	9
Positive		3	0	9		7	5
Nestin	167				0.187			0.005
Negative		28	16	104		141	7
Positive		7	2	10		14	5
FOXA1	175				0.046			0.001
Negative		16	4	23		34	9
Positive		25	13	94		128	4
Bcl2	171				0.098			0.170
Negative		19	6	36		55	6
Positive		19	10	81		106	4

amp: amplified; CISH: chromogenic in situ hybridization; ER: oestrogen receptor; IDC: invasive ductal carcinoma; LN mets: lymph node metastasis; LVI: lympho-vascular invasion; PR: progesterone receptor.
^aMolecular subtypes as defined by Nielsen immunohistochemical surrogate panel.³⁴
Significant P-values are shown in bold.

Back to article page

Table 4 β-Catenin membranous and nuclear expression in 222 invasive breast carcinomas (17C2 clone)

Search

Quick links